// App-Quantinova.ai

AB0743 (2017) : LOW RATES OF MAJOR ADVERSE CARDIAC EVENTS, MALIGNANCIES, AND SERIOUS INFECTIONS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS TREATED WITH APREMILAST FOR ≥156 WEEKS: POOLED ANALYSIS FROM THE ESTEEM AND PALACE 1-3 PHASE 3 TRIALS

Researchers

Presenter

  • A. Kavanaugh

Principal Investigators

  • M. Augustin

  • E. Lespessailles

  • K.A. Papp

  • M. Paris

  • R. Chen

  • D.D. Gladman

  • D.M. Pariser

  • K. Peris

Medical Centers

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg, Hamburg, Germany

  • University of Orléans, Orléans, France

  • Probity Clinical Research, Waterloo, ON, Canada

  • 1Celgene Corporation Summit NJ United States

  • Toronto Western Hospital, Toronto, ON, Canada

  • Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, VA

  • Catholic University of Rome, Rome, Italy

Locations

  • United States

  • Germany

  • France

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbott

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved